Colorado Medicaid and GLP-1s: What Health First Colorado Will and Won't Pay For

No. Health First Colorado, the state’s Medicaid program, does not pay for Wegovy, Zepbound or any other drug when it is used for weight loss, because a state rule lists those agents among the drugs it excludes.^[1] The exclusion turns on why the drug is prescribed, and the state’s drug list does approve Wegovy for heart-risk reduction or the liver disease MASH, and Zepbound for sleep apnea, when a member meets strict criteria.^[1][11] A 2025 state law adds a GLP-1 buy-up option for large employer plans from January 1, 2027, and leaves Medicaid’s rule alone.^[3]

Why doesn't Health First Colorado cover weight-loss drugs?

Federal law gives states a short list of drug classes they may leave out of Medicaid, and drugs used for weight loss are on it.^[5] Colorado took that option in its Medicaid rules. Section 8.800.4.B cites the federal provision and names weight-loss agents first among the excluded categories, alongside fertility drugs and most erectile dysfunction drugs.^[1] Because this is written into the rule, a prior authorization request cannot overcome it. A request built on obesity alone has no route, however well documented.

Can Health First Colorado cover Wegovy or Zepbound for other conditions?

The rule excludes these agents “when used for” weight loss, which leaves room for other uses.^[1] Wegovy’s label includes cutting major cardiovascular events for people who already have heart disease and carry excess weight, plus MASH with stage F2 to F3 scarring, and Zepbound’s includes moderate to severe sleep apnea when obesity is present.^[6][7] Colorado’s preferred drug list puts Wegovy pens and tablets and the Zepbound KwikPen on its preferred side for those uses, each behind its own criteria, and states that a request for weight loss alone will not be approved.^[11]

A sleep apnea approval lasts a year. To renew it, the prescriber must confirm an in-person re-check of the apnea, record improvement in symptoms and review whether the member has kept taking the drug.^[11] A first request goes further when it includes the proof each route asks for: the record of the heart attack, stroke or artery disease, the biopsy or scan that stages the liver, or the sleep study report. Prescribers on the state’s own benefit file with the Colorado Pharmacy Call Center at 888-672-7203, by fax to 833-465-8957 or electronically through CoverMyMeds.^[11] Our guides to Zepbound for sleep apnea and GLP-1s and MASH explain the trial evidence behind those labels.

Which GLP-1s does Health First Colorado prefer for diabetes?

For type 2 diabetes, the state’s preferred GLP-1s are Teva’s liraglutide pen, Mounjaro, Ozempic in pen and tablet form, Trulicity and brand-name Victoza.^[11] Rybelsus, exenatide and liraglutide pens from other makers sit on the non-preferred side. A non-preferred GLP-1 can be approved for a labeled condition other than weight loss after three preferred drugs labeled for that condition have failed or caused problems.^[11]

What does Denver Health's Elevate Medicaid plan cover?

The state’s drug list covers fee-for-service members. It does not apply to members of Rocky Mountain Health HMO or Denver Health’s Elevate Medicaid Choice, which run their own formularies.^[11] Elevate’s is a closed list, so only the drugs on it are covered, and it names weight loss among the exclusions that are “not covered at all even with a prior authorization.”^[2]

For a drug that is not listed, the plan says the prescriber must show why the formulary drugs will not work, and that it uses Health First Colorado’s drug-list guidelines where the state has them, which would bring in the heart, liver and sleep apnea terms above.^[2][11] Prescribers can reach the plan’s pharmacy department at 303-602-2070 or 877-357-0963, or fax a request to 303-602-2081.^[2]

Does Colorado's new obesity law help Medicaid members?

Not directly. Senate Bill 25-048, signed on June 3, 2025, takes effect on January 1, 2027.^[3][4] It requires large group health plans to cover obesity treatment such as nutrition therapy, intensive lifestyle programs and bariatric surgery, and it requires insurers to offer those employers the chance to buy coverage for anti-obesity drugs, including at least one GLP-1.^[3] The drug part is an option the employer may decline, and insurers need not offer it where premiums would not cover expected costs.^[3]

The law changes the insurance code, not the Medicaid rule, and it writes Child Health Plan Plus (CHP+) out on purpose: the CHP+ schedule of services “must not include” the new mandate.^[3] Health First Colorado’s weight-loss exclusion therefore stands.^[1] Coloradans weighing other routes can compare marketplace plans and GLP-1s and state employee plans, where Colorado’s own employee plan has changed course more than once.

What about children and teens?

CHP+ members are covered by the same exclusion in the Elevate formulary, and the 2025 law keeps the new obesity mandate out of CHP+.^[2][3] On the state’s drug list, the heart and sleep apnea routes start at age 18, and the MASH route follows each drug’s labeled minimum age.^[11] For Health First Colorado members under 21, federal law requires Medicaid to provide necessary treatment found through child health screening, even when the state plan does not cover it.^[8] We found no Colorado document that applies that rule to GLP-1s. A family that gets a flat denial can ask in writing for a medical necessity review under EPSDT, the federal child-health benefit.

How do you appeal a denial?

The denial letter sets the deadline and the route, so keep it. Elevate says its letters explain the member’s rights and the appeals process, with details in the member handbook.^[2] An appeal is worth filing when the denial concerns a covered use, such as missing sleep study results. It has nothing to work with when the request rests on weight alone, because the rule excludes that use outright.^[1] Our walkthrough of prior authorization and appeals covers what to send, and the state Medicaid GLP-1 checker compares Colorado with other states.

What are the options without coverage?

Paying cash is the main one. Lilly’s savings card for insured patients excludes Medicaid enrollees.^[9] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s Zepbound KwikPen or vial.^[9][10] Check each offer’s terms on government-program enrollment before you sign up. Our list of the cheapest GLP-1 routes without insurance compares them.